INTERVIEW: ASEAN Preps For First Dengue Vaccine
This article was originally published in PharmAsia News
As the first vaccine against the dengue virus moves towards initial regulatory filings, experts have met in Asia to consider the potential impact of the product and issues related to its availability.
You may also be interested in...
In line with similar initiatives by Japan on other regulatory fronts, the country's Agency for Medical Research and Development is building up its partnerships and presence in Asia.
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.